Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit

Rhea-AI Summary

Revolution Medicines (Nasdaq: RVMD), a precision oncology company, will participate in the Cowen 2nd Annual Virtual Oncology Innovation Summit on May 20-21, 2021. Steve Kelsey, M.D., will present in a fireside chat on May 21 at 12:40 p.m. Eastern. The company focuses on developing targeted therapies for RAS-addicted cancers, with a pipeline including RAS(ON) Inhibitors like RMC-6291 and RMC-6236, and RAS Companion Inhibitors such as RMC-4630. Revolution Medicines leverages advanced drug discovery methods to create innovative small molecules aimed at treating challenging cancer variants.

REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Cowen 2^nd Annual Virtual Oncology Innovation Summit. Steve Kelsey, M.D., president, research and development, will be the featured speaker in a fireside chat at the event.

Details of the company’s participation are as follows:

• Cowen 2^nd Annual Virtual Oncology Innovation Summit
  Conference Date: May 20-21, 2021
  Fireside Chat Time/Date: 12:40 p.m. Eastern on Friday, May 21, 2021
  Format: Virtual conference

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

FAQ

What is the date of the Cowen 2nd Annual Virtual Oncology Innovation Summit for Revolution Medicines?

The Cowen 2nd Annual Virtual Oncology Innovation Summit will take place on May 20-21, 2021.

When is the fireside chat featuring Revolution Medicines?

The fireside chat with Revolution Medicines will occur on May 21, 2021, at 12:40 p.m. Eastern.

Who will represent Revolution Medicines at the Cowen summit?

Steve Kelsey, M.D., president of research and development, will be the featured speaker for Revolution Medicines.

What is the focus of Revolution Medicines?

Revolution Medicines focuses on developing targeted therapies for RAS-addicted cancers.

What are some key products in Revolution Medicines' pipeline?

Key products in the pipeline include RAS(ON) Inhibitors like RMC-6291 and RMC-6236, and RAS Companion Inhibitors such as RMC-4630.